A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors

被引：0
|
作者：
Yu, X. [1 ]
Zhang, J. [2 ]
Liu, R. [2 ]
Deng, Y. [3 ]
Cai, Y. [3 ]
Sun, Y. [4 ]
Dang, Q. [4 ]
Hong, W. [5 ]
Song, Z. [6 ]
Guo, S. [2 ,7 ]
Gao, S.
Su, W. [8 ]
Shi, M. [8 ]
Fan, S. [8 ]
Zhang, B. [8 ]
Pan, B. [8 ]
Ren, Y. [8 ]
Wang, J. [8 ]
Zhong, C. [8 ]
Ma, L. [8 ]
机构：
[1] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China
[4] Shandong Canc Hosp & Inst, Phase Clin Study Ctr 1, Jinan, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Med Oncol, Canc Hosp, Hangzhou, Peoples R China
[6] Univ Chinese Acad Sci, Canc Hosp, Phase Clin Study Ward 1, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[7] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
[8] HUTCHMED China Ltd, R&D, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77MO
引用
收藏
页码：S1496 / S1497
页数：2
相关论文
共 50 条
  • [21] A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors
    Ahnert, Jordi Rodon
    Spigel, David R.
    Kremer, Jill
    Jin, Leah
    Benhadji, Karim Adnane
    Gil, Maciej
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
    Pant, Shubham
    Burris, Howard A., III
    Moore, Kathleen
    Bendell, Johanna C.
    Kurkjian, Carla
    Jones, Suzanne F.
    Moreno, Ofir
    Kuhn, John G.
    McMeekin, Scott
    Infante, Jeffrey R.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 87 - 93
  • [23] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
  • [24] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
    Ben George
    Richards, Donald A.
    Edenfield, William Jeffory
    Warner, Steven L.
    Mouritsen, Lars
    Bishop, Reyna
    Anthony, Stephen Patrick
    Bearss, David
    Vogelzang, Nicholas J.
    Whatcott, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
    Shubham Pant
    Howard A. Burris
    Kathleen Moore
    Johanna C. Bendell
    Carla Kurkjian
    Suzanne F. Jones
    Ofir Moreno
    John G. Kuhn
    Scott McMeekin
    Jeffrey R. Infante
    Investigational New Drugs, 2014, 32 : 87 - 93
  • [26] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [27] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Joerger, Markus
    Calvo, Emiliano
    Laubli, Heinz
    Lopez, Juanita
    Alonso, Guzman
    de la Fuente, Elena Corral
    Hess, Dagmar
    Konig, David
    Perez, Vicky Sanchez
    Bucher, Christoph
    Jethwa, Sangeeta
    Garralda, Elena
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [28] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [29] A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Varga, A.
    Soria, J. C.
    Hollebecque, A.
    LoRusso, P.
    Vaishampayan, U.
    Okrah, K.
    Huang, S. M. A.
    Murray, E.
    Sanabria-Bohorquez, S.
    Tagen, M.
    Dokainish, H.
    Mueller, L.
    Burris, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [30] A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Varga, Andrea
    Soria, Jean-Charles
    Hollebecque, Antoine
    LoRusso, Patricia
    Bendell, Johanna
    Huang, Shih-Min A.
    Wagle, Marie-Claire
    Okrah, Kwame
    Liu, Lichuan
    Murray, Elaine
    Sanabria-Bohorquez, Sandra M.
    Tagen, Michael
    Dokainish, Hatem
    Mueller, Lars
    Burris, Howard
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1229 - 1236
12345